PMID

Data

Article Title

Organization

Synthesis and Characterization of Fatty Acid Conjugates of Niacin and Salicylic Acid.

Catabasis Pharmaceuticals

Synthesis and evaluation of (E)-2-(acrylamido)cyclohex-1-enecarboxylic acid derivatives as HCA1, HCA2, and HCA3 receptor agonists.

Latvian Institute Of Organic Synthesis

Identification of Hydroxybenzoic Acids as Selective Lactate Receptor (GPR81) Agonists with Antilipolytic Effects.

TBA

(1aR,5aR)1a,3,5,5a-Tetrahydro-1H-2,3-diaza-cyclopropa[a]pentalene-4-carboxylic acid (MK-1903): a potent GPR109a agonist that lowers free fatty acids in humans.

Arena Pharmaceuticals

Discovery of SCH 900271, a Potent Nicotinic Acid Receptor Agonist for the Treatment of Dyslipidemia.

TBA

Pyrazole acids as niacin receptor agonists for the treatment of dyslipidemia.

Merck Research Laboratories

GPR109a agonists. Part 1: 5-Alkyl and 5-aryl-pyrazole-tetrazoles as agonists of the human orphan G-protein coupled receptor GPR109a.

Merck Research Laboratories

Nicotinic acid receptor agonists differentially activate downstream effectors.

Arena Pharmaceuticals

SAR studies of C2 ethers of 2H-pyrano[2,3-d]pyrimidine-2,4,7(1H,3H)-triones as nicotinic acid receptor (NAR) agonist.

Merck Research Laboratory

Progress in structure based drug design for G protein-coupled receptors.

Heptares Therapeutics

The discovery of high affinity agonists of GPR109a with reduced serum shift and improved ADME properties.

Merck Research Laboratories

Structure-activity relationships of trans-substituted-propenoic acid derivatives on the nicotinic acid receptor HCA2 (GPR109A).

Leiden University

Discovery of a Potent Nicotinic Acid Receptor Agonist for the Treatment of Dyslipidemia

TBA

Spiroindolones, a potent compound class for the treatment of malaria.

Swiss Tropical And Public Health Institute

Pyrido pyrimidinones as selective agonists of the high affinity niacin receptor GPR109A: optimization of in vitro activity.

F. Hoffmann-La Roche

GPR109a agonists. Part 2: pyrazole-acids as agonists of the human orphan G-protein coupled receptor GPR109a.

Merck Research Laboratories

Discovery of pyrazolyl propionyl cyclohexenamide derivatives as full agonists for the high affinity niacin receptor GPR109A.

Merck Research Laboratories

Anthranilic acid replacements in a niacin receptor agonist.

Merck

Potent tricyclic pyrazole tetrazole agonists of the nicotinic acid receptor (GPR109a).

Arena Pharmaceuticals

Discovery of a biaryl cyclohexene carboxylic acid (MK-6892): a potent and selective high affinity niacin receptor full agonist with reduced flushing profiles in animals as a preclinical candidate.

Merck Research Laboratories

5-N,N-Disubstituted 5-aminopyrazole-3-carboxylic acids are highly potent agonists of GPR109b.

Arena Pharmaceuticals

Discovery of novel tricyclic full agonists for the G-protein-coupled niacin receptor 109A with minimized flushing in rats.

Merck Research Laboratories

Nicotinic acid receptor agonists.

Arena Pharmaceuticals

Molecular modeling aided design of nicotinic acid receptor GPR109A agonists.

Merck Research Laboratories

Discovery of pyrazolopyrimidines as the first class of allosteric agonists for the high affinity nicotinic acid receptor GPR109A.

Merck Research Laboratories

3-(1H-tetrazol-5-yl)-1,4,5,6-tetrahydro-cyclopentapyrazole (MK-0354): a partial agonist of the nicotinic acid receptor, G-protein coupled receptor 109a, with antilipolytic but no vasodilatory activity in mice.

Arena Pharmaceuticals

Discovery of orally bioavailable and novel urea agonists of the high affinity niacin receptor GPR109A.

Merck Research Laboratories

3-Nitro-4-amino benzoic acids and 6-amino nicotinic acids are highly selective agonists of GPR109b.

Arena Pharmaceuticals

Fluorinated pyrazole acids are agonists of the high affinity niacin receptor GPR109a.

Arena Pharmaceuticals

Agonist lead identification for the high affinity niacin receptor GPR109a.

Arena Pharmaceuticals

Analogues of acifran: agonists of the high and low affinity niacin receptors, GPR109a and GPR109b.

Arena Pharmaceuticals

Affinity and kinetics study of anthranilic acids as HCA2 receptor agonists.

Leiden University

Discovery of coumarin-dihydroquinazolinone analogs as niacin receptor 1 agonist with in-vivo anti-obesity efficacy.

Csir-Central Drug Research Institute

Synthesis and evaluation of (E)-2-(5-phenylpent-2-en-4-ynamido)cyclohex-1-ene-1-carboxylate derivatives as HCA2 receptor agonists.

Latvian Institute Of Organic Synthesis